Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: Relationship with silibinin levels

Richard D. Verschoyle, Peter Greaves, Ketan Patel, Debbie A. Marsden, Karen Brown, William P. Steward, Andreas J. Gescher

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Silibinin, a flavonolignan from milk thistle seeds, possesses cancer chemopreventive properties in rodent models of carcinogenesis. We tested the hypotheses that silibinin or silipide, silibinin formulated with phospholipids, delays tumour development in TRAMP or ApcMin mice, genetic models of prostate or intestinal malignancies, respectively. Mice received silibinin or silipide with their diet (0.2% silibinin equivalents) from weaning. Intervention with silipide reduced the size of well differentiated TRAMP adenocarcinomas by 31%. Silipide and silibinin decreased the incidence of poorly differentiated carcinomas by 61% compared to mice on control diet. Silipide decreased plasma levels of insulin-like growth factor (IGF)-1 by 36%. Levels of circulating IGF binding protein (IGFBP)-3 in mice on silipide or silibinin were 3.9- or 5.9-fold, respectively, elevated over those in control TRAMP mice. In ApcMin mice silibinin, but not silipide, had only a marginal adenoma number-reducing effect. The results cautiously support the advancement of silipide to the stage of clinical investigation in prostate cancer.

Original languageEnglish
Pages (from-to)898-906
Number of pages9
JournalEuropean Journal of Cancer
Volume44
Issue number6
DOIs
StatePublished - Apr 2008
Externally publishedYes

Keywords

  • Chemoprevention
  • IGF
  • Preclinical models
  • Silibinin

Fingerprint

Dive into the research topics of 'Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: Relationship with silibinin levels'. Together they form a unique fingerprint.

Cite this